Roivant Sciences (ROIV) PT Raised to $16 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ROIV Hot Sheet
Price: $36.91 -1.63%
Rating Summary:
13 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
13 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Goldman Sachs analyst Corinne Jenkins raised the price target on Roivant Sciences (NASDAQ: ROIV) to $16.00 (from $14.00) while maintaining a Buy rating.
You May Also Be Interested In
- Citi raises Roivant Sciences price target to $56 from $46
- Regeneron Pharma (REGN) PT Raised to $1,020 at Raymond James
- Encompass Health Corp (EHC) PT Raised to $155 at Raymond James
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
